The role of T cells in tumor radiotherapy combined with immunotherapy and gastrointestinal adverse events
REVIEW|更新时间:2025-02-28
|
The role of T cells in tumor radiotherapy combined with immunotherapy and gastrointestinal adverse events
“Immunotherapy combined with radiotherapy is a new strategy for tumor treatment, but normal tissue side effects hinder its development. This article analyzes the role of immune cells in tumor radiotherapy combined with immunotherapy and intestinal side effects, providing guidance for understanding the pathogenesis and treatment strategies.”
Journal of Radiation Research and Radiation ProcessingVol. 39, Issue 1, Pages: 15-20(2021)
SHI Xiaolin (female) was born in March 1996, and graduated from Soochow University in 2019. Now she is a graduate student at Soochow University, majoring in radiation medicine.
LIU Fenju, professor, doctoral supervisor, E-mail: fangsh@suda.edu.com
基金信息:
National Natural Science Foundation of China(31770912;81602793);the Science and Technology Development Plan of Suzhou(sys2018015);the Opening Foundation of State Key Laboratory of Radiation Medicine and Protection(GZK1201805)
SHI Xiaolin,ZHANG Haowen,LIU Fenju.The role of T cells in tumor radiotherapy combined with immunotherapy and gastrointestinal adverse events[J].Journal of Radiation Research and Radiation Processing,2021,39(01):15-20.
SHI Xiaolin,ZHANG Haowen,LIU Fenju.The role of T cells in tumor radiotherapy combined with immunotherapy and gastrointestinal adverse events[J].Journal of Radiation Research and Radiation Processing,2021,39(01):15-20. DOI: 10.11889/j.1000-3436.2021.rrj.39.010102.
The role of T cells in tumor radiotherapy combined with immunotherapy and gastrointestinal adverse events